Mohr E, et al. - Researchers retrospectively assessed early efficacy and safety of delamanid (Dlm) for rifampicin-resistant tuberculosis treatment in a programmatic setting in South Africa with high HIV prevalence. Assessment included 12-month interim outcomes, sputum culture conversion (SCC) by months-2 and 6, serious adverse events (SAEs), and QTcF data. Of 103 patients initiated Dlm; 79(77%) were HIV-positive. In this large cohort of difficult-to-treat patients, favorable early treatment response and good tolerability of the treatment was demonstrated. Dlm availability should be ensured, specifically for those that cannot be treated with conventional regimens and/or with limited treatment options.